Company Directory

Small molecule drug discovery targeting rare genetic diseases and oncology

Tay Therapeutics is a drug discovery company developing targeted small molecule therapies for rare genetic diseases and cancer. Its platform uses stop codon read-through technology to restore production of functional proteins disrupted by premature stop codon mutations, with programmes targeting oncology, cystic fibrosis, Duchenne muscular dystrophy, and epidermolysis bullosa. The company previously discovered and out-licensed two BET inhibitor programmes to VYNE Therapeutics, which are advancing in clinical trials for immuno-inflammatory conditions.

Global pharma company in immunology, vaccines, and oncology

GSK is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of medicines and vaccines. Its pipeline and portfolio span respiratory and immunology, oncology, HIV (through its specialist subsidiary ViiV Healthcare), and infectious diseases including vaccines. The company operates major UK sites including its global R&D hub at Stevenage Bioscience Catalyst, manufacturing facilities at Barnard Castle, Ware, and Montrose, and its global headquarters in London's Knowledge Quarter.

Antibodies, proteins and immunoassays for life science research

Proteintech Europe is the UK and European subsidiary of Proteintech Group, a US-based manufacturer of research reagents. The company produces antibodies, recombinant proteins, nanobodies and immunoassay kits for life science research, with a catalogue covering more than 13,000 protein targets. Additional product lines include human cell-expressed cytokines and growth factors in research and GMP grades, ELISA kits, and nanobody-based affinity reagents. The Manchester site supports commercial and technical operations for UK and European markets.

CRO specialising in oncology, inflammation and respiratory disease models

Axis Bioservices is a preclinical contract research organisation providing bespoke in vitro and in vivo study services for pharmaceutical, biotechnology and academic clients. Specialist capabilities span oncology tumour models, inflammatory disease models including rheumatoid arthritis and pulmonary fibrosis, and respiratory disease models for conditions such as COPD and asthma. Services cover efficacy, mechanistic, and pharmacokinetic studies tailored to individual drug development programmes.

Fibroblast immunology platform targeting cancer and inflammatory disease

Mestag Therapeutics is a clinical-stage biotechnology company developing first-in-class antibody therapies targeting activated fibroblasts to modulate immune responses in cancer and inflammatory disease. Its lead programme, MST-0312, is a bispecific antibody designed to induce tertiary lymphoid structures in solid tumours to drive anti-tumour immunity. A second programme targets a stromal inhibitory receptor to address inflammatory conditions including rheumatoid arthritis, IBD, and lupus.

Generative AI platform for TCR therapy design and immune repertoire analysis

Synteny Biotechnology is a biotechnology company developing a platform that combines high-throughput TCR-antigen data generation with generative AI to design precision T cell receptor therapies for cancer. The platform addresses a critical bottleneck in the field, namely the scarcity of paired TCR-epitope interaction data, using protein language models to engineer TCRs with improved tumour specificity and reduced cross-reactivity. The company applies this platform to an internal pipeline of TCR bispecific therapeutic candidates.

Target discovery platform and antibody-based therapies for oncology

Oxford BioTherapeutics is an Oxford-based clinical-stage oncology company discovering and developing first-in-class antibody-based cancer therapies. Its proprietary platform identifies novel membrane protein targets directly from patient tumour samples, enabling the development of ADCs, immuno-oncology antibodies, T-cell engagers, and CAR-T targets. The company licenses discovered targets and development candidates to major pharmaceutical partners including Bristol Myers Squibb, Roche, GSK, and Boehringer Ingelheim.

UK commercial base for a rare metabolic disease biotech

Amicus Therapeutics UK is the British subsidiary of Amicus Therapeutics, a US-listed biotechnology company focused on rare metabolic diseases. The company develops enzyme replacement therapies and gene therapies targeting lysosomal storage disorders, with approved medicines for Pompe disease and Fabry disease. The UK office in Marlow serves as the commercial and medical affairs base for Great Britain and Ireland.

Clinical-stage therapeutics for advanced liver disease

Yaqrit is a clinical-stage biotechnology company developing treatments for patients with advanced liver disease, including cirrhosis and acute-on-chronic liver failure. Its pipeline includes an oral ammonia scavenger for hepatic encephalopathy, an extracorporeal liver support device, and a microbiome-based therapeutic. Multiple programmes are in Phase 2–3 development. The company's science originates from over two decades of research by Professor Rajiv Jalan and his team at University College London and the Royal Free Hospital.

ECM-targeted drug discovery platform for fibrosis and solid tumours

Engitix is a preclinical-stage biotechnology company developing therapeutics that target the extracellular matrix (ECM) in fibrosis and solid tumours. Its proprietary discovery platform integrates one of the largest ECM bioarchives with AI and machine learning to identify disease-specific targets and biomarkers. Internal programmes target fibro-inflammatory diseases and solid tumours, with partnered drug discovery collaborations with Takeda Pharmaceuticals and Dompé farmaceutici. Engitix was spun out of University College London's Institute for Liver and Digestive Health.

In vitro biology CRO for immunology and oncology drug discovery

BioMedha is a pre-clinical contract research organisation specialising in in vitro biology for early-stage drug discovery. The company provides assay development, target validation, compound screening, and mechanism of action studies across immunology, oncology, immuno-oncology, and inflammation therapeutic areas. Capabilities include whole blood and immune cell functional assays, flow cytometry, cytokine and Luminex multiplex assays, cell imaging, and discovery toxicology. BioMedha is an HTA authorised establishment with an on-site blood donor panel.

Specialist distributor of transplant diagnostics and molecular biology products

VH Bio is a specialist distributor of life science research and diagnostic products serving the United Kingdom and Republic of Ireland. The company focuses on four areas: transplant and HLA diagnostics, molecular biology, immunology, and cell biology. Its portfolio of approximately 10,000 products is sourced from global manufacturing partners, and VH Bio holds exclusive UK and ROI distribution rights for several suppliers. Products are dispatched from a dedicated warehouse and cold storage facility in Gateshead.